GLP-1 Medication, Migraine, and Intracranial Hypertension in Women

A condition that is, functionally, a women's disease

Idiopathic intracranial hypertension (IIH) — sometimes still called pseudotumor cerebri — causes headaches, visual disturbance and, if untreated, permanent vision loss from elevated pressure around the brain, and it overwhelmingly affects women of reproductive age with excess weight. That skew is so pronounced that when researchers ran the first randomised, placebo-controlled trial testing a GLP-1 receptor agonist for IIH, they enrolled sixteen participants — all women, because that is who the condition affects¹. This is one of the clearest examples on this site of a condition that isn't "worse in women" or "different in women" — it is, in practical terms, a condition of women, and coverage of GLP-1s and neurological health that doesn't center that fact is missing the point entirely.

What the exenatide trial actually found

The 2023 trial used telemetric pressure catheters for continuous, objective intracranial pressure monitoring — not a proxy like symptom scores — in women with active IIH randomised to subcutaneous exenatide or placebo. Exenatide significantly lowered intracranial pressure at 2.5 hours, at 24 hours, and out to 12 weeks, with no serious safety signals¹. What makes this notable isn't just that it worked — it's the timeline: a meaningful pressure drop within *hours* is far too fast to be explained by weight loss, which points to a more direct effect of GLP-1 receptor signaling on pressure regulation rather than IIH improving purely as a downstream consequence of shedding weight¹. Since then, a 2025 systematic review of GLP-1 receptor agonists in IIH found the signal held up across the small additional evidence base that has accumulated², and real-world, propensity-matched data on tirzepatide specifically found a similar pattern of benefit³, including reduced need for the neurosurgical shunting procedures IIH sometimes requires⁴. This remains early-stage evidence — a sixteen-person phase 2 trial is not a practice-changing landmark on its own — but it is a real, randomised, mechanistically-supported signal in a condition with genuinely limited treatment options.

The more common but less specific link: migraine

Migraine is a separate condition from IIH, but the two overlap in an important way: both are substantially more common in women, and both show a real relationship with body weight. Migraine affects women roughly three times more often than men, and a body of research has specifically examined how that intersects with obesity — higher weight is associated with both greater migraine frequency and greater severity in women⁵. A meta-analysis of surgical and non-surgical weight loss found migraine frequency improved with weight loss generally⁶, and more directly relevant here, a 2025 prospective pilot study added liraglutide as an add-on treatment specifically in patients with obesity and high-frequency or chronic migraine, with encouraging early results⁷. This is thinner evidence than the IIH data — a small pilot study, not a confirmatory trial — but it points the same direction: for women whose migraine burden is intertwined with weight, a GLP-1's effect may extend beyond metabolic outcomes.

What this means in practice

If you have IIH or a personal history of unexplained headaches with visual symptoms — blurred or dimmed vision, especially with position changes, or pulsing sounds in your ears — that is worth naming explicitly to a GLP-1 prescriber, both because the emerging evidence suggests real potential benefit and because IIH needs its own dedicated monitoring (vision testing, and sometimes lumbar puncture or imaging) that a weight-loss-focused program alone won't provide. If chronic migraine is your primary concern, framing a GLP-1 discussion around headache frequency specifically, not just weight, is reasonable given the pilot data — though this remains a secondary benefit to discuss, not a primary indication a provider should be treating with a GLP-1. Both conditions cross paths with hormones in ways our cycle and hormones guide explores from a different angle, and — notably — a published case report has already described a woman successfully using exenatide for co-occurring IIH and PCOS, underscoring how much these conditions cluster together in the same patients⁸. This guide is educational only and not medical advice.